Medicare Approves New Technology Add-On Payments Of Up To $53,000 For SynCardia's Total Artificial Heart Through FY 2011

CMS Encourages SynCardia to Submit New Technology Add-On Application / If And When Freedom(TM) Portable Driver Undergoing Clinical Study Receives FDA Approval

(PresseBox) ( Tucson AZ USA, )
On Aug. 16, the US Centers for Medicare and Medicaid Services (CMS) published its FY 2011 Hospital Inpatient Prospective Payment System (PPS) final rule, approving new technology addon payments of up to $53,000 for the SynCardia temporary Total Artificial Heart (TAHt) through FY 2011. The decision is effective Oct 1 2010.

CMS stated in its ruling that, "Commenters supported our proposal to continue addon payments for the TAHt... We agree with the commenters that, for patients with biventricular heart failure, the TAHt continues to represent a substantial clinical improvement."

Syncardia Systems, Inc., manufacturer of the Total Artificial Heart, informed CMS of the company's recent use of the 13.5 lb Freedom(TM) portable driver, which provides increased mobility so that stable patients who are eligible may leave the hospital while waiting for a donor heart. SynCardia asserted that this new driver further demonstrates that the Total Artificial Heart represents a substantial clinical improvement.

SynCardia also noted that the use of this portable driver increased the operating costs of the Total Artificial Heart and requested that the new technology addon payment be increased accordingly. However, CMS noted that because the Freedom driver is undergoing an Investigational Device Exemption (IDE) clinical study and is not FDAapproved, it is unable to increase the new technology addon payments for FY 2011.

CMS stated in its ruling, "We would encourage the manufacturer to submit a new technology addon payment application if and when it expects to receive FDA approval for... the Freedom driver."

SynCardia's Total Artificial Heart has been approved for new technology addon payments since FY 2009. It is the world's only FDA, Health Canada and CE approved Total Artificial Heart.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an